What is BioMarin Pharmaceuticals's revenue?

BioMarin Pharmaceuticals (BMRN) generated $3.2B in revenue over the trailing twelve months, up 9.9% year over year.

Is BioMarin Pharmaceuticals profitable?

BioMarin Pharmaceuticals reported $501.0M in net income over the trailing twelve months, a 16.8% net margin.

What are BioMarin Pharmaceuticals's profit margins?

Gross margin is 76.5% and operating margin is 19.9%, with a 16.8% net margin.

What is BioMarin Pharmaceuticals's earnings per share?

BioMarin Pharmaceuticals's diluted EPS over the trailing twelve months is $2.56.

Where does BioMarin Pharmaceuticals's income statement data come from?

Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

BioMarin Pharmaceuticals BMRN Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Total revenue	$766.21M+2.8%	$874.57M+17.0%	$776.13M+4.1%	$825.41M+15.9%	$745.15M+14.8%
Total cost of revenue	$195M+28.7%	$275.71M+103%	$140.09M-25.7%	$150.09M+15.0%	$151.56M+21.1%
Gross profit	$571.21M-3.8%	$598.86M-2.0%	$636.05M+14.1%	$675.32M+16.1%	$593.59M+13.4%
Gross margin	74.6%-5.1pp	68.5%-13.3pp	82%+7.2pp	81.8%+0.1pp	79.7%-1.0pp
Research and development	$178.8M+12.6%	$192.41M+10.9%	$409.48M+121%	$161.31M-12.2%	$158.73M-22.6%
Selling, general and administrative	$258.29M+25.3%	$446.21M+67.4%	$268.42M+5.9%	$232.28M-11.7%	$206.12M-8.8%
Total costs & expenses	$636.57M+22.1%	$919.18M+56.9%	$822.83M+30.2%	$548.52M-7.3%	$521.25M-7.0%
Operating income	$129.64M-42.1%	——	-$46.69M-141%	$276.89M+130%	$223.89M+153%
Operating margin	16.9%-13.1pp	——	-6%-21.3pp	33.5%+16.6pp	30%+16.4pp
Interest expense	$14.96M+422%	$2.78M+7.8%	$2.58M-13.1%	$2.68M-25.0%	$2.86M-19.3%
Other income (expense), net	$5.37M+324%	——	——	$649K-34.1%	$1.27M+1,098%
Income before income taxes	$141.2M-40.7%	$0-100%	-$26.32M-120%	$297.87M+125%	$238.09M+126%
Income tax expense	$35.68M-31.9%	$19.42M-56.6%	$4.42M-84.4%	$57.34M+130%	$52.4M+210%
Net income	$105.53M-43.2%	——	-$30.74M-129%	$240.53M+124%	$185.69M+109%
Net margin	13.8%-11.1pp	——	-4%-18.2pp	29.1%+14.1pp	24.9%+11.3pp
Diluted earnings per share	$0.54-43.2%	——	-$0.16-129%	$1.23+124%	$0.95+107%
EBITDA	$146.05M-40.6%	$23.22M-87.5%	-$28.21M-121%	$295.45M+101%	$245.96M+112%
EBITDA margin	19.1%-13.9pp	2.7%-22.1pp	-3.6%-21.5pp	35.8%+15.2pp	33%+15.2pp
EBIT	$129.64M-42.1%	$2.78M-98.3%	-$46.69M-141%	$276.89M+130%	$223.89M+153%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about BioMarin Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioMarin Pharmaceuticals's revenue?: BioMarin Pharmaceuticals (BMRN) generated $3.2B in revenue over the trailing twelve months, up 9.9% year over year.
Is BioMarin Pharmaceuticals profitable?: BioMarin Pharmaceuticals reported $501.0M in net income over the trailing twelve months, a 16.8% net margin.
What are BioMarin Pharmaceuticals's profit margins?: Gross margin is 76.5% and operating margin is 19.9%, with a 16.8% net margin.
What is BioMarin Pharmaceuticals's earnings per share?: BioMarin Pharmaceuticals's diluted EPS over the trailing twelve months is $2.56.
Where does BioMarin Pharmaceuticals's income statement data come from?: Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.